Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

PURPOSE: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker of AR-targeted therapy resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Sowalsky, Adam G., Figueiredo, Ines, Lis, Rosina T., Coleman, Ilsa, Gurel, Bora, Bogdan, Denisa, Yuan, Wei, Russo, Joshua W., Bright, John R., Whitlock, Nichelle C., Trostel, Shana Y., Ku, Anson T., Patel, Radhika A., True, Lawrence D., Welti, Jonathan, Jimenez-Vacas, Juan M., Rodrigues, Daniel Nava, Riisnaes, Ruth, Neeb, Antje, Sprenger, Cynthia T., Swain, Amanda, Wilkinson, Scott, Karzai, Fatima, Dahut, William L., Balk, Steven P., Corey, Eva, Nelson, Peter S., Haffner, Michael C., Plymate, Stephen R., de Bono, Johann S., Sharp, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378683/
https://www.ncbi.nlm.nih.gov/pubmed/35695870
http://dx.doi.org/10.1158/1078-0432.CCR-22-0851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378683/
https://www.ncbi.nlm.nih.gov/pubmed/35695870
http://dx.doi.org/10.1158/1078-0432.CCR-22-0851

Ejemplares similares